Nature Medicine paper confirms clinical utility of liquid biopsies in routine care for lung cancer Cohort study finds significant OS benefit in NSCLC with targetable ctDNA alterations

IU starts mobile lung cancer screening program

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center and IU Health began a mobile lung cancer screening program, which includes a 40-foot truck with a CT scanner.

March 07, 2025

Vol.51 No.09

Clinical Roundup

Investigational therapy shrinks drug-resistant NSCLC by activating NK cells, study finds

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging an attack from natural killer cells in an animal model, a study led by UT Southwestern Medical Center researchers shows. The findings, published in the Journal for ImmunoTherapy of Cancer, could lead to new types of immunotherapy that rely on this novel strategy.

February 21, 2025

Vol.51 No.07

Drugs & Targets

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

FDA granted priority review to Boehringer Ingelheim’s new drug application for BI 1810631 (zongertinib) for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have HER2 mutations and who have received prior systemic therapy.

February 21, 2025

Vol.51 No.07

Cancer History Project Podcast

20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect

Two decades ago, the discovery of the EGFR mutation transformed lung cancer treatment. The finding led to dramatically improved survival rates and ushered in the era of precision medicine and molecular profiling for lung cancer.

February 14, 2025

Vol.51 No.06

By Yiqing Wang

ACS report: Cancer mortality continues to drop despite rising incidence in women

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men.

January 17, 2025

Vol.51 No.02

By Yiqing Wang

Clinical Roundup

ctDNA levels linked to recurrence risk in lung cancer, study finds

Personalis, Inc., in collaboration with professor Charles Swanton and his colleagues at London’s Francis Crick Institute and University College London, published new results from their TRACERx lung cancer study in Nature Medicine.

January 17, 2025

Vol.51 No.02

Nature Medicine paper confirms clinical utility of liquid biopsies in routine care for lung cancer

Cohort study finds significant OS benefit in NSCLC with targetable ctDNA alterations

YOU MAY BE INTERESTED IN

IU starts mobile lung cancer screening program

Investigational therapy shrinks drug-resistant NSCLC by activating NK cells, study finds

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect

ACS report: Cancer mortality continues to drop despite rising incidence in women

ctDNA levels linked to recurrence risk in lung cancer, study finds

Renew today!

Subscriber content

Never miss an issue!

Login